Huseyin S. Karakilic

Internal Medicine

1221 Pine Grove Ave
Port Huron, MI 48060

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1 publications

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.

Journal: NPJ precision oncology

Published: November 22, 2022

Showing 1-1 of 1

Last Updated: 09/26/2026